Question-and-Answer Session
Operator
(Operator Instructions) Your first question comes from Matthew Kaplan – Ladenburg Thalmann & Co.
Matthew Kaplan – Ladenburg Thalmann & Co.
Could you first start off talking about the Phase 2 diabetes program that you’re planning and then also the cardiovascular or cardio metabolic you’re planning in terms of the time line and points involved in both those studies and when we should expect to see data with those?
Steven Engle
Let me begin by making sure that I introduce Dr. Alan Solinger, our Vice President of Immunology at the company and Alan will speak to the programs.
Dr. Alan Solinger
We’re very pleased that our Phase 1 studies were very successful and gave us much more information than we had originally anticipated. We are in the process of initiating our early Phase 2 program in diabetes as well as evaluating additional input from our potential partners and from our key opinion leaders, especially having met many of them up at the most recent diabetes meetings.
So there will be future announcements as to the exact details of these trials as they are initiated later this year.
As far as the cardiovascular diseases, this has been a very fruitful area of research from our pre-clinical group and when this is added to the available data that’s in the literature based on IL1 blockade in animal models as well as potential data coming from two ongoing human studies, we feel this is a very lively area for further clinical development and as we go further, we should be announcing more details on these studies, probably later this year or the early part of 2010.
Matthew Kaplan – Ladenburg Thalmann & Co.
So in terms of data from either of these studies, it’s really kind of later in 2010 or second half?
Dr. Alan Solinger
Right. What we’ve said is based on the time frames we’re looking at, we think we’ll have interim data in the third quarter of next year, that is 2010 that would be available from the first study.
Matthew Kaplan – Ladenburg Thalmann & Co.
In the diabetes study?
Dr. Alan Solinger
Yes.
Matthew Kaplan – Ladenburg Thalmann & Co.
And then in terms of cardiovascular, you haven’t given any guidance with that yet?
Dr. Alan Solinger
Not yet. Again, as this very exciting data has come out and since we spoke to you last, we’ve not only been to Montreal for the IDF Conference, but at that conference we held a thought leader meeting. That is, we brought in some very world class expert physicians to talk to about which studies should now run based on the new data.
- To read the full transcript on Seeking Alpha, click here »
